Full Year Results Presentation For the 12 months ended 30 June 2020 14 September 2020
Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Abcam plc ("Abcam“, or the “Company”) . The sole purpose of this presentation is to provide information to research analysts and investors in connection with their review of the Company. This presentation does not purport to be all inclusive or to contain all of the information that the analysts may consider material or desirable in analysing the Company or developing their models. The information contained herein is not a substitute for an analyst or investors’ independent evaluation and analysis. No representation, warranty or undertaking, express or implied, is made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained herein, and nothing in the presentation is, or shall be relied upon as a promise or representation. Neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability whatsoever (in negligence, whether direct or indirect, in contract, tort or otherwise) for any errors, omissions or any losses however arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. Forward-looking statements This presentation may contain forward-looking statements, which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting Abcam. In some cases, you can identify forward-looking statements by the following words: “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “seek,” “believe,” “estimate,” “predict,” “potential,” “continue,” “contemplate,” “possible” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. They are not historical facts, nor are they guarantees of future performance. Forward- looking statements are subject to many risks and uncertainties, including (1) the impact of a regional or global health pandemic, including COVID-19; (2) challenges in implementing our strategies for revenue growth, developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; (3) failure to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; (4) any discontinuation or reduction in our customers’ spend on research, development, production or other scientific endeavors; (5) failure to successfully use, access and maintain information systems and implement new systems to handle our changing needs; (6) cyber security risks; (7) failure to successfully manage our current and potential future growth; (8) any significant interruptions in our operations; (9) failure of our products to satisfy applicable quality criteria, specifications and performance standards; and (10) failure to maintain our brand and reputation; among other risks. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as of the date of this presentation and accordingly you should not place undue reliance on such statements. Moreover, new risks emerge from time to time, and it is not possible for Abcam to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements Abcam may make. Abcam cautions readers against relying on these forward-looking statements. Neither Abcam, nor its advisors nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Neither Abcam nor its advisors undertakes any obligation to update any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results of changes in expectations except as may be required by law. Abcam’s actual future results, performance and events and circumstances may be materially different from these expectations. Non-IFRS Measures This presentation contains certain financial measures that are not presented in accordance with the International Financial Reporting Standards (“IFRS”), including, but not limited to, Adjusted Operating Profit, Adjusted Operating Profit Margin, Return on Capital Employed (“ROCE”) and Free Cash Flow. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing Abcam’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to profit for the year, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. Abcam’s presentation of these measures may not be comparable to similarly titled measures used by other companies. Please see the appendix to this presentation for a reconciliation of these measures to the closest comparable IFRS measure. Statements/opinions/views All opinions and estimates in this presentation constitute the reasonable belief of Abcam as of the date of this presentation but are subject to change without notice. Abcam is not rendering legal or accounting advice through this material; readers should contact their legal and accounting professionals for such information. Information subject to change The information contained herein is subject to change, without notice, at the discretion of Abcam, and Abcam does not undertake to revise or update this information in any way. The information contained in this presentation is being provided only for the purposes of general background information about Abcam. Third party data Some information contained herein has been obtained from other third party sources and has not been independently verified by Abcam. Abcam makes no representations as to the accuracy or the completeness of any of the information herein. Neither Abcam nor any of its advisers, representatives and their respective affiliates, officers, employees or agents involved in or related to compiling, computing or creating the data makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof) and all such parties hereby expressly disclaim, to the maximum extent permitted by law and regulation, any and all responsibility or liability as to the accuracy, completeness or reasonableness of the information provided. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Abcam or the proposed offering. 2
Abcam plc ⼁ 2019/20 Full Year Results ⼁ 14 September 2020 Agenda › Our purpose, people and culture › 2020 Financial Performance and Outlook › 2020 Strategy Update: Progress toward our long-term goals 3 3
Our purpose, people and culture Alan Hirzel CEO 4
Abcam plc ⼁ 2019/20 Full Year Results ⼁ 14 September 2020 Our purpose, people and culture Abcam, working toward better scientific and social outcomes To provide superior reagents capable of accelerating and de-risking research, used by more scientists across a wider section of the scientific community, resulting in more people with better health and wellbeing. → → → An Abcam goal aligned to the UN Sustainable Development Goal 3 % of life science publications in Custom projects undertaken Number of products validated on 3 rd party platforms or for which an Abcam product is with partners since 2013 cited 1 diagnostic use >50% >2,000 >450 1. Source: CiteAb, 2019 5
Abcam plc ⼁ 2019/20 Full Year Results ⼁ 14 September 2020 Our purpose, people and culture Our people and culture are dedicated to that purpose Global Employee NPS +52%pts (‘14 to ‘20) FY14 FY15 FY16 FY17 FY18 FY19 FY20 6
Abcam plc ⼁ 2019/20 Full Year Results ⼁ 14 September 2020 Our purpose, people and culture We continue to grow and develop our global team, always prioritising their safety and wellbeing ~390 ~670 USA EMEA Global team >200 >400 ~430 2,000 PhDs LAB BASED 1,500 ASIA PAC 1,000 500 0 FY14 FY15 FY16 FY17 FY18 FY19 FY20 7
Recommend
More recommend
